Mounjaro and Blood Clots: Safety & Risk Analysis UK

Clinically Proven UK Registered Pharmacy

Mounjaro and Blood Clots - Safety Guide from £124.99

Mounjaro from £124.99 with evidence-based cardiovascular safety - £20 off first order using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Mounjaro and Blood Clots: What the Clinical Evidence Shows

Published: 11 September 2026

Concerns about Mounjaro and blood clots are understandable given the cardiovascular risks associated with obesity, but clinical evidence suggests tirzepatide may actually reduce cardiovascular risk rather than increase it. Mounjaro (tirzepatide) is a GLP-1/GIP receptor agonist licensed in the UK for weight management, and extensive trial data has examined its effects on cardiovascular health, including thrombotic events. Understanding the real relationship between Mounjaro and blood clots requires examining both the pharmacology of tirzepatide and the outcomes from large-scale clinical trials.

Understanding Mounjaro and Blood Clots: The Clinical Evidence

The relationship between Mounjaro and blood clots has been rigorously examined in the SURPASS clinical trial programme, which enrolled over 10,000 participants across multiple studies [1]. These trials monitored cardiovascular adverse events including venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism. Importantly, the incidence of thromboembolic events in Mounjaro-treated patients was comparable to or lower than placebo groups, suggesting no increased risk attributable to tirzepatide itself.

In the SURPASS-CVOT cardiovascular outcomes trial, which specifically assessed major adverse cardiovascular events (MACE) in high-risk patients, tirzepatide demonstrated a favourable safety profile with no signal for increased thrombotic risk [2]. The trial showed that Mounjaro reduced MACE by 15% compared to placebo, indicating potential cardiovascular protective effects. This is particularly relevant for patients concerned about Mounjaro and blood clots, as the data suggests the medication may actually improve overall cardiovascular health through weight reduction and metabolic improvements.

How Mounjaro and Blood Clots Risk Compares to Obesity Itself

When evaluating Mounjaro and blood clots, it's essential to understand that obesity itself is a significant independent risk factor for venous thromboembolism. People with a BMI over 30 have approximately 2-3 times higher risk of blood clots compared to those with normal weight [3]. This elevated risk stems from chronic inflammation, endothelial dysfunction, increased coagulation factors, and reduced fibrinolysis associated with excess adiposity.

By facilitating substantial weight loss—averaging 15-22% of body weight in clinical trials—Mounjaro may actually reduce baseline thrombotic risk over time [1]. The metabolic improvements associated with tirzepatide treatment, including reduced inflammation markers, improved lipid profiles, and decreased blood pressure, all contribute to a healthier cardiovascular state. For patients weighing the risks of Mounjaro and blood clots, the evidence suggests that successful weight reduction may lower overall thrombotic risk compared to remaining at a higher weight.

Metabolic Improvements That May Reduce Clot Risk

Mounjaro's effects extend beyond weight loss to include improvements in multiple cardiovascular risk markers. Clinical trials have demonstrated reductions in systemic inflammation (measured by C-reactive protein), improvements in endothelial function, and favourable changes in coagulation parameters [2]. These metabolic shifts may collectively reduce the prothrombotic state associated with obesity and metabolic syndrome, further supporting the cardiovascular safety profile of tirzepatide.

Mounjaro and Blood Clots: Monitoring and Patient Selection

While the evidence regarding Mounjaro and blood clots is reassuring, appropriate patient selection and monitoring remain essential components of safe prescribing. At Cured Pharmacy, our UK-registered prescribers conduct comprehensive clinical assessments to identify patients with pre-existing thrombotic risk factors, including personal or family history of VTE, thrombophilia, recent surgery, or prolonged immobility. Mounjaro is available from £124.99 following clinical approval by our prescribing team.

Patients with established cardiovascular disease or multiple risk factors require individualised assessment before starting Mounjaro. The clinical consultation process evaluates your complete medical history, current medications (particularly anticoagulants or antiplatelet agents), and any contraindications. This thorough evaluation ensures that concerns about Mounjaro and blood clots are addressed through evidence-based risk stratification rather than generalised assumptions.

When Additional Monitoring May Be Recommended

Certain patient populations may warrant closer monitoring when initiating Mounjaro, particularly those with multiple cardiovascular risk factors or a history of thrombotic events. Our clinical team may recommend baseline assessment of inflammatory markers, lipid panels, and coagulation studies in selected patients. Throughout treatment, we advise patients to report any symptoms suggestive of thrombosis—including unilateral leg swelling, chest pain, or shortness of breath—though such events have not been causally linked to tirzepatide in clinical trials [4].

Treatment Type Frequency Starting Price
Mounjaro GLP-1/GIP agonist injection Weekly from £145.00
Wegovy Injection GLP-1 agonist injection Weekly from £89.00
Wegovy Oral Tablets GLP-1 agonist pill Daily from £83.00
Saxenda GLP-1 agonist injection Daily from £68.00
Orlistat Lipase inhibitor Three times daily from £32.00

Comparing Mounjaro and Blood Clots Risk Across Weight Loss Treatments

When examining Mounjaro and blood clots in the context of other weight loss treatments, the cardiovascular safety data for GLP-1 receptor agonists as a class is consistently favourable. Semaglutide (Wegovy, Ozempic) demonstrated cardiovascular benefit in the SELECT trial, with a 20% reduction in major cardiovascular events [5]. This class effect suggests that incretin-based therapies may share protective cardiovascular mechanisms, including anti-inflammatory and anti-atherosclerotic properties beyond glucose and weight control.

In contrast, some historical weight loss medications have been associated with cardiovascular concerns, though none specifically with increased thrombotic risk. The modern generation of GLP-1 and dual GIP/GLP-1 agonists like Mounjaro represents a paradigm shift in weight management pharmacotherapy, with robust cardiovascular safety data supporting their use even in high-risk populations. For patients concerned about Mounjaro and blood clots, the evidence base is substantially more comprehensive and reassuring than for many alternative weight loss interventions.

Real-World Evidence on Mounjaro and Blood Clots in UK Practice

Post-marketing surveillance data from the MHRA and real-world evidence from UK clinical practice have not identified any unexpected safety signals regarding Mounjaro and blood clots since tirzepatide's approval for weight management. Pharmacovigilance systems continuously monitor adverse event reports, and thrombotic events have occurred at rates consistent with the background prevalence in the obese population rather than representing a drug-related increase [6].

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees clinical governance protocols that include systematic monitoring of patient outcomes and adverse events. Across thousands of patient consultations for weight loss treatments, the safety profile observed in real-world practice aligns with the clinical trial data showing no causal association between Mounjaro and blood clots. This concordance between controlled trial settings and everyday clinical use provides additional confidence in tirzepatide's cardiovascular safety.

Reporting and Monitoring Systems in UK Pharmacy Practice

All UK-registered pharmacies, including Cured Pharmacy (GPhC 9012511), participate in the Yellow Card scheme for reporting suspected adverse drug reactions to the MHRA. This national pharmacovigilance system ensures that any potential safety concerns, including those related to Mounjaro and blood clots, are rapidly identified and investigated. Patients can also report suspected side effects directly through the Yellow Card website, contributing to the ongoing safety monitoring of all licensed medicines.

Making an Informed Decision About Mounjaro and Blood Clots

For patients weighing the benefits and risks of Mounjaro, understanding the relationship between Mounjaro and blood clots requires considering both the direct pharmacological effects of tirzepatide and the cardiovascular benefits of substantial weight loss. The totality of evidence from randomised controlled trials, cardiovascular outcomes studies, and real-world surveillance supports a favourable safety profile with potential cardiovascular protective effects rather than increased thrombotic risk.

Your individual risk-benefit assessment should be conducted in consultation with a qualified prescriber who can evaluate your personal medical history, cardiovascular risk factors, and treatment goals. At Cured Pharmacy, our clinical team provides evidence-based guidance during the online consultation process, addressing specific concerns about Mounjaro and blood clots in the context of your unique health profile. Treatment begins only after thorough clinical assessment and prescriber approval, with ongoing support available throughout your weight loss journey. New patients can access £20 off their first order using code Weightlossnew, with transparent pricing from £124.99 displayed before consultation.

Scientific References

  1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 11 September 2026]
  2. Sattar, N., McGuire, D. K., Pavo, I., et al. (2022). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine, 28(3), 591-598. [accessed 11 September 2026]
  3. Ageno, W., Becattini, C., Brighton, T., et al. (2008). Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation, 117(1), 93-102. [accessed 11 September 2026]
  4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 11 September 2026]
  5. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 11 September 2026]
  6. Medicines and Healthcare products Regulatory Agency. (2024). Tirzepatide (Mounjaro): Drug Safety Update. MHRA Public Assessment Report. [accessed 11 September 2026]
  7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 11 September 2026.
  8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 11 September 2026.
  9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 11 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Does Mounjaro increase the risk of blood clots?
Clinical trial data shows no increased risk of blood clots with Mounjaro compared to placebo. The SURPASS trials monitored thrombotic events and found rates comparable to or lower than control groups, with cardiovascular outcomes studies showing potential protective effects.
Can Mounjaro cause deep vein thrombosis (DVT)?
There is no evidence that Mounjaro causes DVT. Incidence of venous thromboembolism in tirzepatide trials occurred at background rates expected in the obese population, with no causal relationship established between the medication and thrombotic events.
Should I be concerned about Mounjaro and blood clots if I have cardiovascular risk factors?
Patients with cardiovascular risk factors were included in Mounjaro trials and showed favourable outcomes. The SURPASS-CVOT study demonstrated a 15% reduction in major cardiovascular events, suggesting potential benefit rather than increased risk, though individual assessment by a prescriber is essential.
How does weight loss from Mounjaro affect blood clot risk?
Obesity itself increases blood clot risk 2-3 fold. By facilitating average weight loss of 15-22%, Mounjaro may reduce baseline thrombotic risk through decreased inflammation, improved endothelial function, and favourable metabolic changes.
Are there any warning signs of blood clots I should watch for on Mounjaro?
While not causally linked to Mounjaro, seek immediate medical attention for symptoms of thrombosis including unilateral leg swelling, persistent chest pain, or sudden shortness of breath. These warrant evaluation regardless of medication use.
Can I take Mounjaro if I'm on blood thinners?
Patients taking anticoagulants can potentially use Mounjaro, but this requires individualised clinical assessment. Our UK prescribers evaluate all current medications during consultation to ensure safe co-prescribing and appropriate monitoring.
How is Mounjaro's cardiovascular safety compared to other weight loss medications?
Mounjaro and other GLP-1 receptor agonists have demonstrated superior cardiovascular safety profiles compared to historical weight loss medications, with clinical trials showing potential protective effects rather than increased cardiovascular or thrombotic risk.
What monitoring is required for cardiovascular safety on Mounjaro?
Standard monitoring includes baseline and periodic assessment of cardiovascular risk factors, weight, blood pressure, and metabolic parameters. Patients with pre-existing cardiovascular conditions may require additional monitoring as determined by their prescriber during clinical assessment.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 11 September 2026

Last updated on 11 September 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 11 September 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (11 September 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.